Shinji Tanaka

Prof. Shinji Tanaka


Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in EBioMedicine
Verified
Journal Article
Open access
SSShu Shimada
Shu Shimada
KMKaoru Mogushi
Kaoru Mogushi
YAYoshimitsu Akiyama
Yoshimitsu Akiyama
TFTakaki Furuyama
Takaki Furuyama
SWShuichi Watanabe
Shuichi Watanabe
Shinji TanakaShinji Tanaka
Shinji Tanaka
Hepatocellular carcinoma (HCC) is a heterogeneous disease with various etiological factors, and ranks as the second leading cause of cancer-related mortality worldwide due to multi-focal recurrence. We herein identified three major subtypes of HCC by performing integrative analysis of two omics data sets, and clarified that this classification was closely correlated with clinicopathological factors, immune profiles and recurrence patterns. In the test study, 183 tumor specimens surgically resected from HCC patients were collected for unsupervised clustering analysis of gene expression signatures and comparative analysis of gene mutations. These results were validated by using genome, methylome and transcriptome data of 373 HCC patients provided from the Cancer Genome Atlas Network. In addition, omics data were obtained from pairs of primary and recurrent HCC. Comprehensive molecular evaluation of HCC by multi-platform analysis defined three major subtypes: (1) mitogenic and stem cell-like tumors with chromosomal instability; (2) CTNNB1-mutated tumors displaying immune suppression; and (3) metabolic disease-associated tumors, which included an immunogenic subgroup characterized by macrophage infiltration and favorable prognosis. Although genomic and epigenomic analysis explicitly distinguished between HCC with intrahepatic metastasis (IM) and multi-centric HCC (MC), the phenotypic similarity between the primary and recurrent tumors was not correlated to the IM/MC origin, but to the classification. Identification of these HCC subtypes provides further insights into patient stratification as well as presents opportunities for therapeutic development. FUND: Ministry of Education, Culture, Sports, Science and Technology of Japan (16H02670 and 18K19575), Japan Agency for Medical Research and Development (JP15cm0106064, JP17cm0106518, JP18cm0106540 and JP18fk0210040).

1 July 2012 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
RARama Adikrisna
Rama Adikrisna
Shinji TanakaShinji Tanaka
Shinji Tanaka
SMShunsuke Muramatsu
Shunsuke Muramatsu
AAArihiro Aihara
Arihiro Aihara
DBDaisuke Ban
Daisuke Ban
SAShigeki Arii
Shigeki Arii

1 August 2012 in Seminars in Oncology
Verified
Journal Article
Closed access
Shinji TanakaShinji Tanaka
Shinji Tanaka
SAShigeki Arii
Shigeki Arii

29 February 2008 in British Journal of Surgery
Verified
Journal Article
Open access
PDF file
Shinji TanakaShinji Tanaka
Shinji Tanaka
SAS Arii
S Arii
MYM Yasen
M Yasen
KMK Mogushi
K Mogushi
NSN T Su
N T Su
HTH Tanaka
H Tanaka
Patterns of cancer recurrence hold the key to prognosis after curative resection. This retrospective study aimed to identify a predictor and therapeutic candidate for aggressive recurrence of hepatocellular carcinoma (HCC). Primary HCC tissues from 107 patients who had curative resection were analysed. Genome-wide gene expression profiles were investigated using a microarray technique, and clustering analysis was carried out based on the first diagnosis of recurrence according to the Milan criteria. Immunohistochemical expression and array-based comparative genomic hybridization (array-CGH) were also assessed. Microarray analysis revealed overexpression of Aurora kinase B, a chromosome passenger protein kinase, as the most significant predictor of the aggressive recurrence of HCC. Aurora kinase B protein expression was significantly associated with aggressive recurrence (P < 0·001) and prognosis (P < 0·001). Multivariable analysis identified Aurora kinase B as the only independent predictor of aggressive recurrence of HCC (P = 0·031). Array-CGH analysis showed that genomic instability was closely related to Aurora kinase B expression (P = 0·011). Aurora kinase B is an effective predictor of aggressive HCC recurrence, in relation to the genomic instability. It might be worth considering as a molecular target for the adjuvant therapy of HCC.

1 January 2009 in Cancer Science
Verified
Journal Article
Closed access
PDF file
Shinji TanakaShinji Tanaka
Shinji Tanaka
SAShigeki Arii
Shigeki Arii

1 May 2018 in The American Journal of Pathology
Verified
Journal Article
Closed access
NCNorimichi Chiyonobu
Norimichi Chiyonobu
SSShu Shimada
Shu Shimada
YAYoshimitsu Akiyama
Yoshimitsu Akiyama
KMKaoru Mogushi
Kaoru Mogushi
MIMichiko Itoh
Michiko Itoh
Shinji TanakaShinji Tanaka
Shinji Tanaka